Resumen de Investigación
iGlarLixi improves glycemic control and reduces insulin injections in type 2 diabetes
Moderate confidence
Low bias
Última actualización 12 de junio de 2026Conclusión Clave:
This study evaluated the effectiveness of insulin glargine-lixisenatide fixed-ratio combination (iGlarLixi) in individuals with type 2 diabetes. It found significant improvements in body weight, BMI, and insulin dosage compared to multiple daily injections (MDI).
Estudio de un Vistazo
Participantes
Intervención
Fixed-ratio combination of basal insulin analog glargine 100 U/mL and glucagon-like peptide 1 receptor agonist lixisenatide (iGlarLixi)
Resultados
Mean change in HbA1c, Mean change in body weight, Mean change in BMI, Mean change in total daily dose of insulin, Mean change in time spent in level 2 hyperglycaemia, Mean change in glycaemia risk index
Financiamiento
No Patrocinado por la Industria
Guarda este estudio y agrega notas a tu biblioteca de investigación.
Efectos Principales
iGlarLixi reduced body weight by −4.19 kg compared to MDI.
iGlarLixi decreased BMI by −1.49 kg/m² compared to MDI.
iGlarLixi reduced total daily insulin dose by −28.57 IU compared to MDI.
Resumen de Evidencia
| Intervention | Outcome | Measured Change | Study Effect |
|---|---|---|---|
 Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) (Medications) |  Body Mass Index (BMI) change (Weight & Anthropometrics) | Decrease | Strong |
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) (Medications) |  Glycemia risk index (Glycemic Control) | Decrease | Strong |
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) (Medications) | HbA1c (Glycemic Control) | No Change | Unclear |
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) (Medications) | Time above 13.9 mmol/L (Glycemic Control) | Decrease | Strong |
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) (Medications) | Total daily insulin dose (Glycemic Control) | Decrease | Strong |
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) (Medications) | Weight change (Weight & Anthropometrics) | Decrease | Strong |
Unlock Full Evidence Analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
La Evidencia Sugiere
- iGlarLixi reduced body weight by −4.19 kg compared to MDI.
- iGlarLixi decreased BMI by −1.49 kg/m² compared to MDI.
- iGlarLixi reduced total daily insulin dose by −28.57 IU compared to MDI.
Tener en Cuenta
- The study was open-label, which may introduce bias.
- The sample size and demographic characteristics were not detailed.
- Long-term effects of iGlarLixi were not assessed.
Entre Líneas
- The study was open-label, which may introduce bias.
- The sample size and demographic characteristics were not detailed.
- Long-term effects of iGlarLixi were not assessed.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Referencia de la Revista
Peter N, Lenka T, Ivana L, et al. Insulin therapy simplification from multiple daily injections to once-daily iGlarLixi in people with type 2 diabetes: a phase IV randomized controlled trial. Diabetes, Obesity & Metabolism. 2025. doi:10.1111/dom.70362
Connected Evidence
Discover how this study fits into the broader diabetes evidence landscape.
This study contributes to evidence on Insulin Therapies and Total daily insulin dose, Insulin Therapies and Body Weight.
Relaciones de evidencia relacionadas
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention–outcome relationships.
Incluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Insulin Therapies Evidence Hub
All studies on Insulin Therapies
2 studies
intervention_hubContributes to Insulin Therapies evidence base.
Total daily insulin dose Evidence Hub
All studies measuring Total daily insulin dose
2 studies
outcome_hubMeasures Total daily insulin dose as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
1 studies
outcome_hubMeasures Body Weight as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en el archivo de evidencia
Jump to pre-filtered views in the evidence archive.
All studies on Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) and Total daily insulin dose
Intervention: Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi)Outcome: Total daily insulin dose
2 results
All studies on Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) and Body Mass Index (BMI) change
Intervention: Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi)Outcome: Body Mass Index (BMI) change
1 results
All studies on Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi)
Intervention: Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi)
2 results
All studies measuring Total daily insulin dose
Outcome: Total daily insulin dose
2 results
All studies measuring Body Mass Index (BMI) change
Outcome: Body Mass Index (BMI) change
1 results
Preguntas que esta evidencia ayuda a responder
Key clinical and research questions this study contributes to.
Does insulin glargine/lixisenatide fixed-ratio combination (iglarlixi) improve Total daily insulin dose?
Based on connected evidence for Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) and Total daily insulin dose.
Does insulin glargine/lixisenatide fixed-ratio combination (iglarlixi) affect Body Mass Index (BMI) change in people with diabetes?
Exploring evidence on Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) and Body Mass Index (BMI) change outcomes.
What does the evidence say about insulin glargine/lixisenatide fixed-ratio combination (iglarlixi) and Weight change?
Review of studies examining Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) and Weight change.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.